JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

A

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

A

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

A

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

A

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

A

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

Search

Simulations Plus Inc

Slēgts

SektorsVeselības aprūpe

14.28 -5.62

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

14.03

Max

15.13

Galvenie mērījumi

By Trading Economics

Ienākumi

3.9M

4.5M

Pārdošana

5.9M

24M

EPS

0.35

Dividenžu ienesīgums

0.48

Peļņas marža

18.669

Darbinieki

212

EBITDA

4.9M

7.2M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+5.33% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

0.48%

2.24%

Nākamie ieņēmumi

2026. g. 13. jūl.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

51M

302M

Iepriekšējā atvēršanas cena

19.9

Iepriekšējā slēgšanas cena

14.28

Ziņu noskaņojums

By Acuity

6%

94%

4 / 348 Rangs Healthcare

Simulations Plus Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 24. apr. 00:00 UTC

Peļņas

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

2026. g. 24. apr. 00:00 UTC

Peļņas

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

2026. g. 23. apr. 23:47 UTC

Tirgus saruna

Gold Edges Lower Amid Ongoing Concerns Over Higher Inflation -- Market Talk

2026. g. 23. apr. 23:43 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 23. apr. 23:43 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 23. apr. 23:43 UTC

Tirgus saruna

Nikkei May Decline Amid Uncertainty Over U.S.-Iran Conflict -- Market Talk

2026. g. 23. apr. 23:13 UTC

Iegādes, apvienošanās, pārņemšana

Trump on Spirit Airlines: 'I Think We'd Just Buy It' -- Update

2026. g. 23. apr. 22:33 UTC

Peļņas

Intel Shares Jump 20% as AI Agents Drive Big Growth -- WSJ

2026. g. 23. apr. 22:17 UTC

Peļņas

PLS Executed Offtake Agreement With Ronbay

2026. g. 23. apr. 22:17 UTC

Peļņas

PLS Secured Up to A$38.1M in Australia Government ARENA Grant Funding

2026. g. 23. apr. 22:16 UTC

Peļņas

PLS Commences Commissioning of Midstream Demonstration Plant

2026. g. 23. apr. 22:15 UTC

Peļņas

PLS Group Reaffirms FY26 Guidance for All Metrics

2026. g. 23. apr. 22:14 UTC

Peļņas

PLS Group 3Q Cash Margin From Operations A$461M at March 31

2026. g. 23. apr. 22:14 UTC

Peļņas

PLS Group 3Q Cash Balance A$1.455 Billion at March 31

2026. g. 23. apr. 22:13 UTC

Peļņas

PLS Group 3Q Unit Operating Cost A$733/Ton CIF, Up 2% on 2Q

2026. g. 23. apr. 22:12 UTC

Peļņas

Correct: PLS Group 3Q Unit Operating Cost A$520/Ton FOB, Down 11% on 2Q

2026. g. 23. apr. 22:12 UTC

Peļņas

PLS Group 3Q Unit Operating Cost US$520/Ton FOB, Down 11% on 2Q

2026. g. 23. apr. 22:11 UTC

Peļņas

PLS Group 3Q Realized Price US$1,867/Ton, Up 61% on 2Q

2026. g. 23. apr. 22:10 UTC

Peļņas

PLS Group 3Q Revenue A$567,000, Up 52% on 2Q

2026. g. 23. apr. 22:09 UTC

Peļņas

PLS Group 3Q Sales 195,700 Tons, Down 16% on 2Q

2026. g. 23. apr. 22:08 UTC

Peļņas

PLS Group 3Q Production 232,400 Tons, Up 12% on 2Q

2026. g. 23. apr. 22:04 UTC

Peļņas

Intel Sales Rise 7% as AI Agents Drive Growth -- WSJ

2026. g. 23. apr. 21:56 UTC

Tirgus saruna
Peļņas

Intel Points to Growing Role of CPUs Amid AI Shifts -- Market Talk

2026. g. 23. apr. 21:48 UTC

Iegādes, apvienošanās, pārņemšana

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

2026. g. 23. apr. 21:27 UTC

Peļņas

Intel CFO: All Demand Signals Point to Growing Role of CPUs in AI Era

2026. g. 23. apr. 21:25 UTC

Peļņas

Intel CFO Expects Factories to Continue Increasing Supply in 3Q, 4Q, but at More Measured Pace Than Previously Expected

2026. g. 23. apr. 21:24 UTC

Peļņas

SAP Stock Rebounds From Software Slaughter. The Cloud Boosted Europe's Tech Titan. -- Barrons.com

2026. g. 23. apr. 21:24 UTC

Peļņas

Blackstone Stock Falls After Earnings. Private Credit Remains in Focus. -- Barrons.com

2026. g. 23. apr. 21:21 UTC

Peļņas

Intel to Look for Unconventional Way to Boost Manufacturing Capacity Through Musk's Terafab Project, CEO Says

2026. g. 23. apr. 21:21 UTC

Peļņas

Intel CEO: He, Elon Musk Believe Global Semiconductor Supply Isn't Keeping Up With Accelerating Demand

Salīdzinājums

Cenas izmaiņa

Simulations Plus Inc Prognoze

Cenas mērķis

By TipRanks

5.33% augšup

Prognoze 12 mēnešiem

Vidējais 16 USD  5.33%

Augstākais 16 USD

Zemākais 16 USD

Pamatojoties uz 3 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

3 ratings

2

Pirkt

1

Turēt

0

Pārdot

Noskaņojums

By Acuity

4 / 348 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat